Eva Hellström-Lindberg group – Myelodysplastic syndromes

Our research aims at improving overall and symptom-free survival in MDS and is pursued along the following lines. The research program focuses on the hemopoietic stem cell malignancy myelodysplastic syndromes (MDS) and include genetic, epigenetic, and cellular studies. The aim is to understand mechanisms for disease progression, leukemic transformation, and erythroid failure.

Group leader

Eva Hellström-Lindberg

Group leader, Professor, Senior physician

Eva Hellström-Lindberg is group leader for Myelodysplastic syndromes, She is a double specialist in hematology and internal medicine since 1993, and Professor of hematology at the Department of Medicine, Huddinge since 2009. She has worked within the translational research field for many years and been actively involved in strategic research questions. Eva has been president for European Association of Hematology as well as for Swedish Society of Hematology.

Group members

Staff

Sara von Bahr Grebäck

PhD, MSc. PA to Eva Hellström-Lindberg

Sara von Bahr Grebäck has a MSc in Molecular Biology from Stockholm University and a PhD in Medical Biochemistry from Karolinska Institutet, Department of Laboratory Medicine (Ingemar Björkhem group). Sara is PA for Professor Eva Hellström Lindberg and Research secretary and Project Coordinator in Hellström Lindberg group

Marios Dimitriou

Associate professor

Gunilla Walldin

Research and biobank nurse

Monika Jansson

Affiliated Lab Manager

Postdocs

Pedro Moura

PhD, Postdoc

Martin Jädersten

MD, PhD, Senior post doc

PhD Students

Projects

Clinical trials

Clinical trials within the Nordic MDS Group encompassing the NMDSG14B pan-Nordic trial aiming to develop personalized MRD markers for patients undergoing stem cell transplantation and where the major goal is to prevent clinical relapse.

Integrated genomics analyses

Integrated genomics analyses (targetseq and RNAseq) based on large well-annotated MDS biobanks to develop precision medicine for MDS

Studies of the MDS subtype refractory anemia

Studies of the MDS subtype refractory anemia with ring sideroblasts, MDS-RS, exploring the biological consequences of mutations in the splice factor gene SF3B1 for HSC clonal advantage and erythroid development.

Research support

  • Knut and Alice Wallenberg Foundation
  • The Swedish Cancer Society
  • The Scientific Research Council
  • Stockholm County Council Research funds
  • Cancer Society in Stockholm
  • Nordic Cancer Union

Selected publications*

*co-authoring other PIs at HERM

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E. Nat Med. 2020 Oct;26(10):1549-1556.

SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM)
Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres M, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase DT, Tuechler H, Greenberg PL, Ogawa S, Hellström-Lindberg E, Cazzola M. Blood. 2020 Jul 9;136(2):157-170.

Letter: Acid secretion by gastric mucous membrane
Durbin RP
Am J Physiol 1975 Dec;229(6):1726

A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes.
Elvarsdottir EM, Mortera-BlancoT, Dimitriou M, Bouderlique T, Jansson M, Hofman IJF, Conte S, Karimi Arzenani M, Sander B, Douagi I, Woll P and Hellström-Lindberg E. Leukemia. 2020 Jan;34(1):271-282.

Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes
Rydén J, Edgren G, Karimi M, Walldin G, Tobiasson M, Wikman A, Hellström-Lindberg E, Höglund P
Leukemia 2019 02;33(2):522-527

SF3B1 mutations in myelodysplastic syndromes with ring sideroblasts arise in multipotent hematopoietic stem cells
Mortera-Blanco T, Dimitriou M, Woll PS, Karimi M. Elvarsdottir E, Conte S. Tobiasson M, Jansson M, Douagi I, Moari M, Saft L, Papaemmanuil E, Jacobsen, SEW. Hellström-Lindberg E, Blood. 2017 Aug 17;130(7):881-890.

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.
Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, De Paepe A, Karimi M, Krjutskov K, Einarsdottir E, Grövdal M, Jansson M, Ben Azenkoud A, Corddedu L, Lehmann S, Ekwall K, Kere J, Hellström-Lindberg E, Ungerstedt J
Oncotarget 2017 Apr;8(17):28812-28825

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
Scharenberg C, Giai V, Pellagatti A, Saft L, Dimitriou M, Jansson M, Jädersten M, Grandien A, Douagi I, Neuberg DS, LeBlanc K, Boultwood J, Karimi M, Jacobsen SE, Woll PS, Hellström-Lindberg E
Haematologica 2017 03;102(3):498-508

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo
Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P, Hokland P, Holm MS, Cazzola M, Malcovati L, Tauro S, Bowen D, Boultwood J, Pellagatti A, Pimanda JE, Unnikrishnan A, Vyas P, Göhring G, Schlegelberger B, Tobiasson M, Kvalheim G, Constantinescu SN, Nerlov C, Nilsson L, Campbell PJ, Sandberg R, Papaemmanuil E, Hellström-Lindberg E, Linnarsson S, Jacobsen SE
Cancer Cell 2014 Jun;25(6):794-808

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts
Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, Stephens PJ, McLaren S, Massie CE, Tarpey PS, Varela I, Nik-Zainal S, Davies HR, Shlien A, Jones D, Raine K, Hinton J, Butler AP, Teague JW, Baxter EJ, Score J, Galli A, Della Porta MG, Travaglino E, Groves M, Tauro S, Munshi NC, Anderson KC, El-Naggar A, Fischer A, Mustonen V, Warren AJ, Cross NC, Green AR, Futreal PA, Stratton MR, Campbell PJ,
N Engl J Med 2011 Oct;365(15):1384-95

Metal substitutions incarbonic anhydrase: a halide ion probe study. Formate assay in body fluids: application in methanol poisoning
Smith RJ, Bryant RG, Makar AB, McMartin KE, Palese M, Tephly TR
Biochem Biophys Res Commun Biochem Med 19751975 Oct Jun;6613(42):1281-6117-26

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression
Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, Hedlund A, Hast R, Schlegelberger B, Porwit A, Hellström-Lindberg E, Mufti GJ
J Clin Oncol 2011 May;29(15):1971-